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a  b  s  t  r  a  c  t
Streptococcus  pyogenes  is  responsible  for infections  as  pharyngitis,  sepsis,  necrotizing  fasciitis  and  strep-
tococcal  toxic  shock  syndrome.  The M protein  is the major  bacterial  antigen  and  consists  of  both
polymorphic  N-terminal  portion  and  a conserved  region.  In  the  present  study,  we  analyzed  the in vitro
ability  of  StreptInCor  a C-terminal  candidate  vaccine  against  S. pyogenes  to  induce  antibodies  to neutral-
ize/opsonize  the  most  common  S. pyogenes  strains  in Sao  Paulo  by  examining  the recognition  by  sera  fromeywords:
treptococcus pyogenes
accine
heumatic fever
mmunization coverage
StreptInCor  immunized  mice.  We  also  evaluated  the  presence  of cross-reactive  antibodies  against  human
heart valve  tissue.  Anti-StreptInCor  antibodies  were  able  to  neutralize/opsonize  at least  5 strains,  show-
ing  that  immunization  with  StreptInCor  is  effective  against  several  S. pyogenes  strains  and  can  prevent
infection  and  subsequent  sequelae  without  causing  autoimmune  reactions.
© 2013  Elsevier  Ltd.  All rights  reserved.
mmune response
. Introduction
Streptococcus pyogenes causes diseases as pharyngitis, impetigo,
treptococcal toxic shock syndrome and necrotizing fasciitis.
heumatic fever (RF), acute streptococcal glomerulonephritis and
heumatic heart disease (RHD) are non-suppurative autoimmune
ost-streptococcal sequelae that arise from a delayed immune
esponse to infection in genetically predisposed individuals [1].
everal markers are described as risk factors for RF/RHD, includ-
ng HLA-DR7, the allele most commonly associated with RHD in
razil and other countries [2].
According to the World Health Organization (WHO), S. pyogenes
s responsible for 15–20% of bacterial pharyngitis cases, which pri-
arily affect 5- to 18-year-old individuals [3]. The incidence of
acterial pharyngitis varies among countries, and even within the
ame country, there are variations in different regions due to age,
ocioeconomic and environmental factors and quality of health ser-
ices [4,5].
∗ Corresponding author at: Laboratório de Imunologia, Instituto do Corac¸ ão
HC-FMUSP), Av. Dr. Eneas de Carvalho Aguiar, 44, 05403-000 Sao Paulo, SP, Brazil.
el.: +55 11 26615901; fax: +55 11 26615953.
E-mail address: luizagui@usp.br (L. Guilherme).
264-410X/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.vaccine.2013.08.043The M protein has been described as the major bacterial anti-
gen [6]. The protein consists of two polypeptide chains in an alpha
double helix coiled-coil that forms ﬁbrils extending up to 60 nm
away from the bacterial surface. It is approximately 450 amino
acids long and is divided into tandem repeat blocks distributed
over four regions (A, B, C and D). The N-terminal portion (regions
A and B) is polymorphic and differences within the ﬁrst 150 amino
acid residues of the A region allow for the classiﬁcation of different
serotypes [7,8]. The C-terminal portion (regions C and D) is highly
conserved, responsible for binding the bacteria to the oropharynx
mucosa and has antiphagocytic properties [6,7].
RF/RHD pathogenesis is related to the production of autoanti-
bodies and autoreactive T cells that recognize and cross-react with
epitopes from both the M protein and human heart tissue by molec-
ular mimicry [9,10] and it was  demonstrated by analyzing the T cell
repertoire that inﬁltrated cardiac tissue and led to damage in RHD
[11].
M1  is the most common strain worldwide and, due to its high
virulence, is involved in invasive and non-invasive infections in
several countries [12,13]. There is a large diversity of strains in
Brazil. The most prevalent strains found in a sample from Sao Paulo
city were the M1,  M6,  M12, M22, M77  and M87 compatible with
those found in the rich districts from Salvador [5,14]. These M-types
are also predominant in most of the world western countries [15].
accine
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esides that, there is a much higher diversity of M-types in the poor
istricts from Salvador and Brasilia typically found in low incomes
egions [5,16].
The classiﬁcation of strains according to their tissue tropism for
hroat (A–C pattern), skin (D pattern) or both (E pattern) is based
n the organization of emm  and emm-like genes located in the mga
ocus within S. pyogenes genome and constitute the base for emm
attern genotyping [17,18]. Strains belong to A–C pattern, as the
1,  M6  and M12, has been historically associated with rheumatic
ever [10,19] while the M22  and M87  strains belong to the E pat-
ern are considered a group associated with both throat and skin
nfections [19,20].
The development of a vaccine against S. pyogenes would provide
any beneﬁts, preventing streptococcal infections and sequelae.
everal vaccine development studies have focused on the M protein
ue to its high immunogenicity and have been tested since 1923
21,22]. The ﬁrst vaccines used whole inactivated bacteria. The use
f the entire M protein from speciﬁc strains started in 1979, but
he results were not satisfactory. In the 1980s, synthetic peptide
odels were introduced. Later, molecular biology models based on
he N-terminal portion were developed, and hexavalent and 26-
alent vaccines containing the most prevalent serotypes in United
tates entered into phase I/II clinical trials [23]. Simultaneously,
ew approaches for deﬁning protective epitopes were designed
ased on both N and C-terminal regions. Currently, researchers
re studying models that are based on streptococcal antigens other
han the M protein [24].
Approximately 15 years ago, our group started to develop an
ffective vaccine against S. pyogenes. The approach considered how
he immune system could be more effective in inducing a protec-
ive immune response via T and B lymphocytes without triggering
utoimmunity [25].
Brieﬂy, the vaccine is based on amino acid sequences from the
5 protein conserved region (C2 and C3 regions). Reactivity was
valuated by humoral and cellular analyses to deﬁne potentially
rotective epitopes. The B epitope, composed of 22 amino acid
esidues, is linked by 8 amino acid residues to the T epitope, which
onsists of 25 amino acid residues, using a segment of the natu-
al M5  protein. We  synthesized a peptide with 55 residues called
treptInCor (medical ID), which contained both the B and T epitopes
25].
The analysis of StreptInCor sequence binding to different HLA
lass II molecules was conducted using theoretical possibilities of
rocessed peptides to ﬁt into the pockets of antigen presenting
ells (APC), followed by T cell activation via T cell receptor (TCR)
hat stimulates B cells to secrete antibodies with protective poten-
ial. The StreptInCor sequence contain seven potential binding sites
hat were recognized by HLA class II (DRB1*/DRB3*/DRB4*/DRB5*),
aking StreptInCor a candidate vaccine with broad capacity of cov-
rage [26].
The vaccine peptide was tested in animal models. Inbred and
utbred mice showed strong humoral response against StreptIn-
or with high IgG production [27]. Challenge with M1  strain in
mmunized Swiss mice showed a survival rate of 100% for up to
1 days, compared to the control group’s lower survival rate (40%)
28]. HLA class II transgenic mice, that have the capacity of present
he vaccine epitope to the TCR in the context of human molecules,
ere immunized with StreptInCor in aluminum hydroxide (Alum)
nd produced high titers of IgG1 (Th2-dependent IL-4) and IgG2a
Th1-dependent IFN-). Speciﬁc antibodies were observed after a
eriod of one year without reactivity against human heart proteins.
o lesions were observed in several organs [29], indicating that
treptInCor is safe and has protection potential.
In the present study, we analyzed the in vitro ability of anti-
treptInCor antibodies to neutralize/opsonize S. pyogenes strains
requently found in Sao Paulo. We  also analyzed the absence of 32 (2014) 4104–4110 4105
humoral autoimmune reactions against human heart valve tis-
sue.
The results presented here showed that anti-StreptInCor anti-
bodies were able to neutralize/opsonize M1, M5, M12, M22  and
M87  S. pyogenes strains, indicating that the vaccine can be effective
against the bacteria, preventing infection and subsequent sequelae
without causing autoimmune reactions.
2. Methods
2.1. StreptInCor vaccine epitope
The vaccine epitope consists of the following 55 amino acid
residues: KGLRRDLDASREAKKQLEAEQQKLEEQNKISEASRKGLR-
RDLDASREAKKQVEKA. The peptide was synthesized using a
9--ﬂuorenylmethoxy-carbonyl (Fmoc) solid-phase strategy,
puriﬁed by reverse phase high-pressure liquid chromatography
(RP-HPLC, Shimadzu, Japan). Peptide quality was assessed by
matrix-assisted desorption ionization mass spectrometry (MALDI-
ToF, Ettan Maldi Tof Pro, Amersham-Pharmacia, Sweden) as
previously described [25]. Patents PCT-BR07/000184.
2.2. Mice
Inbred BALB/c and outbred Swiss mice with mature immune
system (6- to 8-week-old) speciﬁc pathogen-free from CEMIB (Uni-
camp, Campinas, Brazil) were maintained in autoclaved cages
(Alesco, Brazil) and handled under sterile conditions in the animal
facility at the Tropical Medicine Institute, University of São Paulo,
Brazil. Procedures were performed in accordance with the Brazilian
Committee for animal care and use (COBEA) guidelines approved by
the Tropical Medicine Institute Ethics Committee (project number
002/08).
2.3. Immunization
Mice sera previously immunized with 10 g of StreptInCor
adsorbed onto 60 g of aluminum hydroxide gel (Sigma–Aldrich
Corp., USA) in saline via subcutaneous with two doses 14 days
apart. Animals that received saline plus 60 g of adjuvant were
used as negative controls. Positive controls were immunized with
recombinant streptococcal M1  full protein (clone kindly provided
by Prof. Patrick Cleary, University of Minnesota Medical School, MN,
USA), produced and puriﬁed in our lab. Sera samples were obtained
under light anesthesia by retro-orbital puncture on day 28 fol-
lowing immunization. Samples with high speciﬁc antibody titers
(>1:1.200) detected by Enzyme-Linked Assay Immunoabsorbent
(ELISA) [28] were used.
2.4. S. pyogenes strains
The strains were obtained from patients treated at the Clinical
Hospital, University of Medicine – Sao Paulo, between 2001 and
2008 and identiﬁed by genotyping [30]. The M1,  M5, M6,  M12,
M22  and M87  specimens were cultured on sheep blood agar (Vetec,
Brazil), followed by growth in Todd-Hewitt broth (Himedia, India)
until OD600 of 0.4 and stored at −80 ◦C.
2.5. M protein C-terminal region sequence alignment of different
S. pyogenes strains
Amino acid sequences from the M protein C-terminal region
of M1,  M5,  M6,  M12  and M87  strains were aligned using the
StreptInCor amino acid sequence through the online program
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences are
available at Pubmed (http://www.ncbi.nlm.nih.gov/pubmed),
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wissprot (http://www.uniprot.org/help/uniprotkb) and CDC
http://www.cdc.gov/ncidod/biotech/strep/strepblast.htm). The
lignment was colored using the Jalview 2.7 program with Zapo
taining to indicate the amino acids’ chemical groups.
.6. Neutralization assay by ﬂow cytometry
S. pyogenes isolates were cultured as described in Section 2.4.
he bacteria were incubated with 1:100 BALB/c hyperimmune or
ontrol mice sera (n = 9) for 30 min. After, samples were incu-
ated with murine IgG phycoerythrin (PE) – (Invitrogen, USA)
peciﬁc antibody (1:50) for 30 min. After, washed and ﬁxed in
% paraformaldehyde. Subsequently, 10,000 events were acquired
sing a ﬂow cytometer FACS Canto II (BD Biosciences, USA), and
he results were analyzed using FlowJo software version 3.4.1. Sta-
istical analysis was performed using Mann–Whitney test after
nalyzing normalization using the Shapiro–Wilk test.
.7. S. pyogenes strains Western Blotting
M1  and M5  strains were cultured as described in Section 2.4.
he bacteria were disrupted by sonication (Sonic Dismembrator
0, Termo Fisher Scientiﬁc, Sweden). The proteins were precipi-
ated in TCA/Acetone solution at −20 ◦C and concentrated in ﬁlter
olumns (Millipore, USA). The Bradford assay (Bradford, 1976) was
sed for quantitation of proteins (Bio-Rad, USA). After SDS–PAGE
lectrophoresis, the gel was blotted onto nitrocellulose membranes
31,32], subsequently blocked with Tris-buffered saline containing
% skim milk. The membrane was treated with immunized or con-
rol BALB/c mice sera pools (n = 6), incubated with anti-mouse IgG
lkaline phosphatase and revealed with NBT-BCIP solution (Invi-
rogen, USA). The molecular weight marker used was  Full-range
ainbow (GE Healthcare, Sweden). Membranes and gels images
ere obtained using an ImageScanner photo-scanner with the
canning software Labscan (GE Healthcare, Sweden). Densitom-
try was performed by TL ImageQuant software (GE Healthcare,
weden).
.8. Opsonophagocytic assay
S. pyogenes strains were cultured until they reached an optical
ensity of 0.4–0.5. After, approximately 2.5 × 106 colony-formimg
nits (CFU) were incubated with 1:100 anti-StreptInCor or con-
rol sera (n = 6) from BALB/c mice, previously heat-inactivated by
ncubation at 56 ◦C for 30 min, to destroy the activity of serum com-
lement. Pre-immunization sera from 6 BALB/c mice were used
s negative control. After incubation, 10% of normal mouse serum
NMS) was added as complement source. To stimulate the recruit-
ent of mice immune cells, 10 g of Concanavalin A (Canavalia
nsiformis-ConA, Sigma) was injected intraperitoneally. The ani-
als were sacriﬁced 48 h after injection, and the peritoneal cavity
as washed with 5 mL  of cold PBS on ice. The concentration of per-
toneal cells was adjusted to 4 × 106/ml  in HBSS (Invitrogen, USA)
ontaining 0.01% gelatin (opsonization buffer). The bacteria treated
ith hyperimune or control mice sera were harvested and incu-
ated with 4 × 105 peritoneal cells at 37 ◦C for 45 min  with shaking
220 rpm). Ten-fold dilutions of the samples were performed and
0 L aliquots of each dilution were cultured on blood agar plates.
he count live colonies were performed as previously described
33]. After 20 min, slides of the M1  strain opsonophagocitic assay
ere prepared by cytospin, stained with Instant-Prov (New-
rov, Brazil), subsequently analyzed by light microscopy using an
xion Vision Zeiss Imager A1 and photographed by Axion Vision
oftware (Zeiss, Germany). Statistical analysis was performed using
ruskal–Wallis test. 32 (2014) 4104–4110
2.9. Heart tissue valve Western Blotting
Heart tissue was  obtained from the lysate of a postmortem
normal human mitral valve, separated by SDS–PAGE and blotted
onto nitrocellulose membranes [31,32]. The blots were blocked
with Tris-buffered saline containing 5% skim milk. The membrane
was sequentially treated with a pool (n = 6) of BALB/c or Swiss
immunized mice sera and anti-mouse IgG alkaline phosphatase and
revealed with NBT-BCIP solution (Invitrogen, USA).
3. Results
3.1. Anti-StreptInCor recognized M1  and M5 strains
We  observed that anti-StreptInCor antibodies from the BALB/c
mice sera pool were able to cross-recognize both the M5  and M1
proteins in total protein extracts from each strain (Fig. 1).
3.2. Several streptococcal strains were neutralized by
anti-StreptInCor antibodies
The anti-StreptInCor antibodies from Swiss mice were able
to neutralize the M1,  M5,  M12, M22  and M87  strains by cross-
recognizing the M protein on the bacterial surface with a Median
Fluorescence Intensity (MFI) 2 or 3 times greater than the MFI of
control sera (Fig. 2).
3.3. Anti-StreptInCor antibodies were able to opsonize, and
promote the phagocytosis and death of several strains
Anti-StreptInCor antibodies from BALB/c and Swiss mice were
able to promote opsonophagocytosis and death of the M1, M5,
M12, M22  and M87  strains (Fig. 3a and b, respectively). The amino
acid sequences alignment of the M protein C-terminal region of
the strains used in this study had, on average, 72% identity with
the StreptInCor amino acid sequence (Fig. 3c). The M1,  M6 and
M12  strains had an additional block of 7 amino acids, while the
M87  strain contained two  fewer amino acids than the StreptInCor
sequence. M1  strain was  killed in peritoneal cells by phagocy-
tosis 20 min  after the opsonization assay as observed by optical
microscopy (Fig. 4a–d).
3.4. StreptInCor did not induce autoimmune reactions
No autoreactive antibodies against human heart mitral valve
protein extracts were observed (Fig. 5).
4. Discussion
The development of a vaccine against multiple S. pyogenes
strains without causing autoimmunity will bring numerous ben-
eﬁts to human health. A vaccine would prevent streptococcal
infections and sequelae and could be more effective and longer-
lasting than the currently used treatment.
In addition to have broad coverage against strains, a vaccine
should promote the production of neutralizing and opsonophago-
cytic antibodies, which are the body’s major defense lines against
extracellular microorganisms.
In the 70 and 80s several models of anti S. pyogenes vaccines
were assayed without satisfactory results, however by using new
approaches several models were proposed [24]. Strain-speciﬁc vac-
cines based on recombinant N-terminal portions of the M protein
serotypes most prevalent in the US entered into phase I/II clini-
cal trials [23]. A new approach based on the 30 most prevalent
serotypes is being tested and the results indicate that the vaccine
K.M. De Amicis et al. / Vaccine 32 (2014) 4104–4110 4107
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Tig. 1. Reactivity of sera pool from BALB/c mice immunized with StreptInCor and c
b).  M5 protein extract; lanes: (1) molecular weight marker, (2) anti-recombinant 
ool.  M1  and M5  molecular weights are available at http://www.uniprot.org/help/u
ould evoke cross-protective antibodies capable of covering most
f the serotypes not included in the vaccine design [34]. Therefore,
s the prevalence of strains can vary depending on the region of
he world a vaccine based on the conserved region of the M protein
robably will present a broad coverage.
The StreptInCor is a vaccine model developed from the M5  pro-
ein C-terminal region [25], speciﬁcally located on C2 and C3 region
hat is conserved among the serotypes. It is interesting to note that
he sequences KLEEQNKI that link both the T and B epitopes in the
treptInCor peptide, is located after the C0–C1, C1–C2, C2–C3 con-
erved linkers as showed by McMillan et al. (2013) [19], and this
equence is in accordance with the natural M5  protein segment.
Antibodies induced by the vaccination should be capable of
inding to the same cross-conserved region of the M protein
rom different S. pyogenes strains around the world. This process
ould neutralize the adhesion function, leading to phagocytosis
nd killing by APCs.
We  observed that immunization with StreptInCor in mice
as able to promote the antibody production against C-terminal
ig. 2. Neutralization of different strains by anti-StreptInCor antibodies. Analysis of neutr
he  Median Fluorescence Intensity (MFI) obtained for each serum sample is represented a
P  value < 0.5; **P value < 0.1; ***P value < 0.01; ****P value < 0.001 (Mann–Whitney). Dat
he  error bar represents the standard deviation (SD).ls against M1 and M5 protein extracts. Western blotting of (a), M1 protein extract
ra pool, (3) pre-immune sera pool, (4) control sera pool, (5) anti-StreptInCor sera
tkb. The pool was composed of 6 BALB/c mice sera per group.
epitopes capable of cross-recognizing similar regions in both the
M5 and M1  proteins. In addition, anti-StreptInCor neutralizing
antibodies had the capacity to bind to M1,  M5,  M12, M22  and M87
proteins on the surface of each bacterial cell, opsonizing and lead-
ing to phagocytosis and death as observed in the opsonophagocytic
assays. The M1  strain, the most common worldwide, also one of
the most virulent strains [12], was rapidly killed on the APCs
phagocytosis vacuoles induced by StreptInCor immunization,
as compared with controls. These results indicate the capacity
of anti-StreptInCor antibodies to neutralize/opsonize the most
prevalent strains.
By amino acid sequences alignment in the present study,
we observed that the C-terminal region of the M proteins had,
on average, 72% identity with StreptInCor. The M1, M6 and
M12  have an additional block of 7 amino acid residues in their
sequences, while M87  has two  fewer amino acids than the Strept-
InCor sequence. These differences did not interfere with antibody
recognition, as observed in the opsonization assays with several
strains.
alization of M1, M5,  M12, M22  and M87  strains was performed by ﬂow cytometry;
s data point. Anti-StreptInCor BALB/c mice sera (); control BALB/c mice sera ();
a are representative of three independent experiments with nine mice per group.
4108 K.M. De Amicis et al. / Vaccine 32 (2014) 4104–4110
Fig. 3. Opsonophagocytosis and death of several S. pyogenes strains by mice peritoneal cells. Opsonophagocytosis of M1,  M5,  M12, M22  and M87  strains by anti-StreptInCor
antibodies from: (a) BALB/c mice sera (n = 6), (b) Swiss mice sera (n = 6), immunized with 10 g of StreptInCor or controls. The CFU units obtained at 106 dilution are represented
as  a data point. Anti-StreptInCor BALB/c mice sera (); control BALB/c mice sera (); pre-immune mice sera pool (♦). *P value < 0.5; **P value < 0.1; ***P value < 0.01; ****P
value  < 0.001 (Kruskal–Wallis). Data are representative of three independent experiments with six mice per group. The error bar represents the standard deviation (SD). (c)
C-terminal amino acid sequences from M1,  M5,  M6, M12  and M87  strains aligned with the StreptInCor amino acid sequence; identity percentage is represented in red; (*):
identical  amino acid residues; (-----): lack of residues; (◦) different amino acids from the same chemical group. Colors – blue and red: amino acids with electrically charged
side  chains; green: amino acids with uncharged polar side chains; pink: glycines; light orange: amino acids with hydrophobic side chains. Different colors in the same column
indicate  an amino acid from a different chemical group; ([ ]) natural link between the B and T cell epitopes.
Fig. 4. Opsonization, phagocytosis and death of M1  strain induced by anti-StreptInCor antibodies. Optical microscopy of M1 strain phagocytosis and death within peritoneal
cells  stained with Instant-Prov. Acquisition at ocular lenses 20 min after the opsonization assay. Magniﬁcation 10×,  objective ranged from 20× to 40×. Bacteria treated with
pre-immune control sera (a) magniﬁcation of 200×, (b) magniﬁcation of 400×; bacteria treated with hyperimmune sera (c), magniﬁcation of 200×; (d) magniﬁcation of
400×.  Black arrows: S. pyogenes; red arrows: S. pyogenes phagocytosed by APC; blue arrows: S. pyogenes in APC digestive vacuoles.
K.M. De Amicis et al. / Vaccine 32 (2014) 4104–4110 4109
Fig. 5. Autoimmune reactivity evaluation. No autoimmune antibodies against human heart valve protein extract were observed by Western Blotting. (a) SDS–Page post-
transfer, (b) Western blotting membrane; lanes: (1) molecular weight marker; (2) anti-human myosin antibody; (3) isotype control; (4) pre-immune mice sera pool; (5)
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In addition, M-types amino acid sequences from UniprotKB
atabase were aligned in the Short-Blastp program against Strept-
nCor. The results showed that the StreptInCor sequence is on
verage 71% conserved amongst the 541M protein sequences avail-
ble at the public database. This block of results indicates that
nti-StreptInCor antibodies can bind directly to multiple parts of
he M protein C-terminal sequences due to the repeat blocks of
mino acids. Consequently, differences between StreptInCor and
he M protein sequences do not affect opsonization of the target
train, indicating that StreptInCor have broad capacity of coverage
gainst the diverse M-types around the world.
Previously we showed that StreptIncor can be recognized by
everal HLA class II molecules, making it a candidate vaccine
ith broad capacity of coverage. The binding prediction of the C-
erminal amino acid sequences of the M1,  M5,  M6,  M12  and M87
roteins with different HLA class II molecules shows that the pos-
ibility of recognition/processing of M proteins and peptides in the
ockets (P1, P4, P6 and P9) of different HLA class II molecules agree
ith previous human studies from our group [26].
Another important data present here is that the anti-StreptInCor
psonizing and neutralizing antibodies did not induce cross-
eactivity with human valve protein extracts, indicating the
bsence of cross-reactive antibodies. These results agrees with
revious studies with HLA class II transgenic mice, in which no
ross reactivity against heart-tissue derived proteins and no tissue
esions were observed in several organs up to one year post-
accination [29].
. Conclusions
The present work reinforces the safety of and strong immune
esponse triggered by the StreptInCor mice vaccination. Produc-
ions of antibodies that opsonize and neutralize a broad range of
. pyogenes strains indicate the potential of StreptInCor to prevent
treptococcal infections without causing deleterious reactions.onﬂict of interest
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